2
Clinical Trials associated with Anti-GPC3 CAR-T(Fuda Tumor Hospital of Guangzhou Fuda Medical)A phase I-IIa clinical study offourth-generation chimeric antigen receptor modified autologous T cells targeting phosphatidylinositol proteoglycan-3 (GPC3) for advanced hepatocellular carcinoma
Chimeric Antigen Receptor-Modified T Cell (CAR-T) Immunotherapy for Hepatocellular Carcinoma (HCC) Targeting Glypican-3 (GPC3)
The purpose of this study is to preliminarily evaluate the safety and efficacy of CAR-T cell immunotherapy for GPC3 positive hepatocellular carcinoma.
100 Clinical Results associated with Anti-GPC3 CAR-T(Fuda Tumor Hospital of Guangzhou Fuda Medical)
100 Translational Medicine associated with Anti-GPC3 CAR-T(Fuda Tumor Hospital of Guangzhou Fuda Medical)
100 Patents (Medical) associated with Anti-GPC3 CAR-T(Fuda Tumor Hospital of Guangzhou Fuda Medical)
100 Deals associated with Anti-GPC3 CAR-T(Fuda Tumor Hospital of Guangzhou Fuda Medical)